JAMA Neurol:急性缺血性卒中溶栓前脑微出血负担越高,则脑出血的风险越高

2016-07-24 phylis 译 MedSci原创

重要性,脑微出血(CMBS)已被确立为脑出血一个独立的预测因子。在静脉溶栓治疗(IVT)急性缺血性脑卒中患者(AIS)中,CMB与症状性颅内出血(sICH)的风险的潜在相关性的研究数据是相互矛盾。目的:探讨CMB(IVT 前MRI显示>10 CMBS)与IVT的 AIS患者继发性颅内出血的风险的相关性。数据源:搜索MEDLINE和Scopus数据库确定符合条件的研究。没有语言或其他限制。文献

重要性:脑微出血(CMBS)已被确立为脑出血一个独立的预测因子。在静脉溶栓治疗(IVT)急性缺血性脑卒中患者(AIS)中,CMB与症状性颅内出血(sICH)的风险的潜在相关性的研究数据是相互矛盾。

目的:探讨CMB(IVT 前MRI显示>10 CMBS)与IVT的 AIS患者继发性颅内出血的风险的相关性。

数据源:搜索MEDLINE和Scopus数据库确定符合条件的研究。没有语言或其他限制。文献检索于2015年10月7日进行。该荟萃分析采用了系统综述和荟萃分析(PRISMA)优先申报项目的指导方针,根据流行病学观察性研究的Meta分析进行书写(MOOSE)。

研究的选择:合格的前瞻性研究报道AIS患者IVT前行MRI检查CMB。

数据提取与合成:提取AIS患者IVT预治疗前MRI检查不同CMB患者sICH的发生率,0 CMBS组(CMB缺失),1个或更多的CMBS(CMB存在),1至10的CMB(低到中度的CMB的负担),和超过10CMB(CMB负担)。在提供完整患者信息集的纳入的研究中,进行单独患者数据的荟萃分析。

主要成果和措施:基于欧洲急性卒中协作研究II定义症状性脑出血(任何颅内出血与NHISS恶化≥4)。

结果:纳入了9项研究,包括2479例AIS患者。与不存在CMB的患者相比,存在CMB的患者溶栓后继发性颅内出血的风险升高(RR,2.36;95% CI,1.21-4.61;)。与0到10个CMB(RR,12.10;95% CI,4.36-33.57)或1-10CMB(RR,7.01;95% CI,3.20-15.38)相比,高CMB负担(> 10 CMBS)的AIS患者IVT后sICH风险升高。在个体患者数据的荟萃分析中,校正潜在因素前(未校正OR,31.06;95% CI,7.12-135.44;)后(校正OR,18.17;95% CI,2.39-138.22;),CMB负担与sICH可能性增加相关。

结论与相关性:治疗前MRI 显示的CMB存在和CMB的负担与AIS患者进行IVT治疗发生sICH独立相关。CMB高负担可能包括在AIS患者IVT预测sICH个人风险分层评分。

原始出处:

Tsivgoulis G, Zand R,et al. Risk of Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke and High Cerebral Microbleed Burden: A Meta-analysis. JAMA Neurol. 2016 Jun 1


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1674841, encodeId=67c116e48413d, content=<a href='/topic/show?id=60fb50501b3' target=_blank style='color:#2F92EE;'>#微出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50501, encryptionId=60fb50501b3, topicName=微出血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7927121733, createdName=liuxiaona, createdTime=Tue Apr 25 12:52:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892781, encodeId=e8d31892e819e, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 22 09:52:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806102, encodeId=02d71806102d5, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 03 10:52:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999732, encodeId=ea311999e3259, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 02 14:52:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393540, encodeId=7aa513935405c, content=<a href='/topic/show?id=7ee28485472' target=_blank style='color:#2F92EE;'>#脑微出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84854, encryptionId=7ee28485472, topicName=脑微出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jul 26 06:52:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1674841, encodeId=67c116e48413d, content=<a href='/topic/show?id=60fb50501b3' target=_blank style='color:#2F92EE;'>#微出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50501, encryptionId=60fb50501b3, topicName=微出血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7927121733, createdName=liuxiaona, createdTime=Tue Apr 25 12:52:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892781, encodeId=e8d31892e819e, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 22 09:52:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806102, encodeId=02d71806102d5, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 03 10:52:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999732, encodeId=ea311999e3259, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 02 14:52:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393540, encodeId=7aa513935405c, content=<a href='/topic/show?id=7ee28485472' target=_blank style='color:#2F92EE;'>#脑微出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84854, encryptionId=7ee28485472, topicName=脑微出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jul 26 06:52:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1674841, encodeId=67c116e48413d, content=<a href='/topic/show?id=60fb50501b3' target=_blank style='color:#2F92EE;'>#微出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50501, encryptionId=60fb50501b3, topicName=微出血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7927121733, createdName=liuxiaona, createdTime=Tue Apr 25 12:52:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892781, encodeId=e8d31892e819e, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 22 09:52:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806102, encodeId=02d71806102d5, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 03 10:52:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999732, encodeId=ea311999e3259, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 02 14:52:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393540, encodeId=7aa513935405c, content=<a href='/topic/show?id=7ee28485472' target=_blank style='color:#2F92EE;'>#脑微出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84854, encryptionId=7ee28485472, topicName=脑微出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jul 26 06:52:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1674841, encodeId=67c116e48413d, content=<a href='/topic/show?id=60fb50501b3' target=_blank style='color:#2F92EE;'>#微出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50501, encryptionId=60fb50501b3, topicName=微出血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7927121733, createdName=liuxiaona, createdTime=Tue Apr 25 12:52:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892781, encodeId=e8d31892e819e, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 22 09:52:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806102, encodeId=02d71806102d5, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 03 10:52:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999732, encodeId=ea311999e3259, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 02 14:52:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393540, encodeId=7aa513935405c, content=<a href='/topic/show?id=7ee28485472' target=_blank style='color:#2F92EE;'>#脑微出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84854, encryptionId=7ee28485472, topicName=脑微出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jul 26 06:52:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]
    2017-04-02 yinhl1978
  5. [GetPortalCommentsPageByObjectIdResponse(id=1674841, encodeId=67c116e48413d, content=<a href='/topic/show?id=60fb50501b3' target=_blank style='color:#2F92EE;'>#微出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50501, encryptionId=60fb50501b3, topicName=微出血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7927121733, createdName=liuxiaona, createdTime=Tue Apr 25 12:52:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892781, encodeId=e8d31892e819e, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 22 09:52:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806102, encodeId=02d71806102d5, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jul 03 10:52:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999732, encodeId=ea311999e3259, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 02 14:52:00 CST 2017, time=2017-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393540, encodeId=7aa513935405c, content=<a href='/topic/show?id=7ee28485472' target=_blank style='color:#2F92EE;'>#脑微出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84854, encryptionId=7ee28485472, topicName=脑微出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Tue Jul 26 06:52:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]

相关资讯

Neurology:左心房疾病是缺血性卒中的独立危险因素

背景:最近报道显示左心房疾病是缺血性卒中的独立危险因素,研究者试图探讨心房内传导阻滞(aIAB)是否是脑卒中的独立的危险因素。方法:研究者检查社区动脉粥样硬化风险研究(ARIC)中的14716患者,aIAB和缺血性卒中发生之间的关系(平均年龄54±5.8岁;55%女性;26%为黑人)。在ARIC研究期间(1987-1989),从基线数字心电图识别aLAB患者,并对其进行3次随访研究访问(1990-

Sci Rep: 乙酰胆碱酯酶抑制剂可降低痴呆患者缺血性卒中发生的风险

老年痴呆症患者的卒中发生风险增加。乙酰胆碱酯酶抑制剂(AChEIs)有保护血管内皮功能的作用和抗炎的特性。研究者调查无卒中史的应用AChEIs药物的痴呆患者,缺血性脑卒中的风险。使用1999到2008年台湾国家健康保险数据库中的数据,共有50岁以上的无卒中史的老年痴呆症患者37352例符合条件。竞争风险校正后,采用倾向评分匹配的Cox比例风险模型分析结果。与相匹配的倾向得分相比(240.8/100

Int J Cardiol:LDL-C和非HDL-C水平与缺血性卒中风险增加显著相关

背景:血脂水平与脑卒中发病率之间的相关性关系低于血脂水平和冠心病(CHD)的相关性。目的:评估总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)和甘油三酯水平的地理、种族和民族差异是否与卒中事件的发生相关。方法:从卒中的地理和种族差异的原因研究(REGARDS)中,研究者评估基线无卒中的受试者的LDL-C,HCL-C,TC, non-HDL-C(total- HD

Arthritis Rheum:RA患者暴露于TNFi,不会增加缺血性卒中风险

研究表明,对于类风湿性关节炎患者,与缓解病情的抗风湿药物相比,没有发现肿瘤坏死因子抑制剂和缺血性卒中之间的关系。曼彻斯特大学和索尔福德皇家医院NHS信托基金会的Audrey S. L. Low博士对3271例接受合成DMARD患者和11642例接受TNFi+合成DMARD的患者进行了研究。所有患者有活动性RA,DAS28评分大于3.2,至少完成一次随访的问卷调查。DMARDs组随访的11973人年

Lancet Neurol:阿替普酶有益于缺血性卒中患者的长期生存

阿替普酶对缺血性卒中后患者生存的影响是一个讨论的主题。研究人员在第三次国际卒中试验(IST-3)中报告了静脉注射阿替普酶对缺血性卒中后患者的长期生存效果。 IST-3在12个国家(澳大利亚,欧洲和英国)的156家医院进行,参与者(年龄>18岁)通过电话语音或网络系统以1:1随机分配,在缺血性卒中后6小时内接受静脉注射0.9mg/kg的阿替普酶加标准治疗或单纯标准治疗。研究人员在英国

PLoS One:脑白质疏松症患者缺血性卒中后溶栓治疗,易颅内出血

背景:脑白质疏松症是急性缺血性脑卒中患者中较常见。许多研究结果显示,脑白质疏松症及溶栓后颅内出血的关系结果仍有争议。方法:研究者进行了一项荟萃分析,比较有无脑白质疏松症患者,溶栓后颅内出血的风险。用主客观相结合的方式检索PubMed、EMBASE和Cochrane图书馆,ISI数据库中2015年12月前相关报道。脑白质疏松症及颅内出血有明确定义的原创文章符合条件,对其进行选择和分析。应用漏斗图、E